Hunter C. Smith - 12 Feb 2025 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Signature
/s/ Stephen Vander Stoep, attorney-in-fact for Hunter C. Smith
Issuer symbol
RYTM
Transactions as of
12 Feb 2025
Net transactions value
-$42,347
Form type
4
Filing time
14 Feb 2025, 16:59:13 UTC
Previous filing
11 Feb 2025
Next filing
19 Feb 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RYTM Common Stock Sale $41,672 -739 -0.7% $56.39 105,556 12 Feb 2025 Direct F1
transaction RYTM Common Stock Sale $675 -12 -0.01% $56.22 105,544 12 Feb 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units.